UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 5, 2006
Lifeline Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Colorado
|
|
000-30489
|
|
84-1097796 |
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
6400 South Fiddler’s Green Circle, Suite 1970, Englewood, CO 80111
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (720) 488-1711
6400 South Fiddler’s Green Circle, Suite 1750, Englewood, CO 80111
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
ITEM 7.01 Regulation FD Disclosure
On March 29, 2006, the Company filed on Form 8-K a Regulation FD Disclosure. The exhibit
attached contained two pages of financial information. The graphical information on those pages
did not display correctly, making the information difficult to read.
The pages, in a different format, are attached.
It remains the Company’s policy that it will not provide guidance as to future performance of the
Company or of its operating results.
ITEM 9.01. Exhibits
99.1 Presentation dated “March 06”
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
Date: April 5, 2006
| |
|
|
|
|
| |
LIFELINE THERAPEUTICS, INC.
|
|
| |
By: |
/s/ Gerald
J. Houston |
|
| |
|
Gerald J. Houston |
|
| |
|
Chief Financial Officer |
|
| |
2